Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Date of Report: November 13, 2024
Reporting Period: Single event date (November 13, 2024)
Business Context: The filing serves as a Regulation FD disclosure to make available an updated Investor Presentation intended for use in investor communications. The company is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a corporate presentation rather than a financial statement report.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The primary action is the furnishing of an Investor Presentation as Exhibit 99.1.
Guidance, Outlook, and Risks
Management Commentary: The company has prepared a slide deck for investor presentations. The content of this deck is not included in the filing text but is available on the company's website under the "Investors – Corporate Presentation" section.
Legal Status of Information: The information contained in this Item 7.01 and the accompanying Exhibit 99.1 is furnished and shall not be deemed "filed" under the Securities Exchange Act of 1934. It is not subject to the liabilities of Section 18 of the Exchange Act and shall not be incorporated by reference into any other filings.
Investor Verification Checklist
- Verify the content of the Investor Presentation (Exhibit 99.1) directly on the company's website at the provided URL.
- Confirm that the furnished presentation is not considered "filed" for legal liability purposes under Section 18 of the Exchange Act.
- Review the company's most recent 10-Q or 10-K for actual financial metrics, as this 8-K does not contain numerical financial data.